ArticleVaccine2011
Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.
Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 44 citations in OpenAlex.
- Protective efficacy of a genetically modified attenuated vaccinia virus Tiantan strain against monkeypox virus challenge in a small animal model.Journal of virology · 2026Article
- Construction and characterization of the ORF131 gene deletion strain of lumpy skin disease virus.Virology journal · 2025Article
- Article
- Enhancing the Immunogenicity of Vaccinia Virus.Viruses · 2022Article
- Gene amplification acts as a molecular foothold to facilitate cross-species adaptation and evasion of multiple antiviral pathways.Virus evolution · 2022Article
- Extracellular Vesicles and Their Use as Vehicles of Immunogens.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Genome-Wide Analysis and Molecular Characterization of Orf Virus Strain UPM/HSN-20 Isolated From Goat in Malaysia.Frontiers in microbiology · 2022Article
- Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.Biomedicines · 2021Review
- Enhancing the Protective Immune Response to Administration of a LIVP-GFP Live Attenuated Vaccinia Virus to Mice.Pathogens (Basel, Switzerland) · 2021Article
- Review
- CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development.Viruses · 2018Review
- Article
- Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?Viruses · 2017Review
- Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.Expert review of vaccines · 2017Review
- Generation of an Attenuated Tiantan Vaccinia Virus Strain by Deletion of Multiple Genes.Frontiers in cellular and infection microbiology · 2017Article
- Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators.Vaccine · 2016Article
- Highly immunogenic variant of attenuated vaccinia virus.Doklady. Biochemistry and biophysics · 2016Article
- Experimental Evolution Identifies Vaccinia Virus Mutations in A24R and A35R That Antagonize the Protein Kinase R Pathway and Accompany Collapse of an Extragenic Gene Amplification.Journal of virology · 2015Article
- The evolution of poxvirus vaccines.Viruses · 2015Review
- Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
We show here that the immunogenicity of the Modified Vaccinia Ankara MVA vaccine strain can be improved by deletion of the A35 gene, without diminishing the ability of the virus to replicate. Deletion of the A35 gene resulted in increased virus-specific immunoglobulin production, class switching to IgG isotypes, and virus-specific IFNγ-secreting splenocytes. The MVA35 deletion virus provided excellent protective efficacy against virulent virus challenge. These results suggest that A35 deletion mutant strains will have superior vaccine performance for poxvirus vaccines as well as platform vaccines for other infectious diseases and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.